Portfolio: Biotechnology

Affymax, Inc.
Exited via the public markets

Alinea Pharmaceuticals, Inc.
Diabetes and related metabolic disorders

Allozyne, Inc.
Next generation protein optimization

Alnara Pharmaceuticals
Focused on developing non systemic protein therapeutics for the treatment of metabolic diseases

Arriva Pharmaceuticals, Inc.
Enzyme inhibitor replacement & therapy

ARYX Therapeutics, Inc.
Retro-metabolic drug design